Virios provides pipeline update: IMC-1 Phase 3 partnership discussions, IMC-2 FDA briefing for Long-COVID

Dogwood Therapeutics, Inc.

FDA guidance received for IMC-1 Phase 3 fibromyalgia trial; multiple life science companies reviewing Phase 2 data for partnership.
Briefing materials submitted to FDA for IMC-2 Investigational New Drug application to treat Long-COVID (no approved LC treatments yet).
Filed provisional method-of-use patents for IMC-2 in Long-COVID and Alzheimer's disease, covering through at least 2043.
Cash runway expected to support operations into Q3 2024 due to expense management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.